U.S. markets close in 3 hours 36 minutes

Cellectis S.A. (ALCLS.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
11.52-0.26 (-2.21%)
At close: 5:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.78
Open11.80
Bid0.00 x 0
Ask0.00 x 0
Day's Range11.52 - 11.94
52 Week Range10.25 - 28.45
Volume62,261
Avg. Volume82,202
Market Cap528.16M
Beta (5Y Monthly)2.21
PE Ratio (TTM)N/A
EPS (TTM)-2.36
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Monthly information on share capital and company voting rights

      (Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights08/31/202145,465,31051,067,217 About CellectisCellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-

    • GlobeNewswire

      Cellectis Announces Participation in Five Investor Conferences

      NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences. 11th Annual Biotech Symposium (Goldman Sachs) Date: Tuesday, September 7, 2021Time: 8AM-6PM (GMT) Citi’s 16th

    • Motley Fool

      Cellectis SA (CLLS) Q2 2021 Earnings Call Transcript

      At this time, I'll now turn the conference over to Eric Dutang, Chief Financial Officer. Thank you, and welcome everyone to Cellectis' second quarter 2021 corporate update and financial results conference call. Joining me on the call today with prepared remarks is Dr. Andre Choulika, our Chief Executive Officer; Dr. Carrie Brownstein, our Chief Medical Officer; and Steve Doares, our Senior Vice President of U.S. Manufacturing will be joining for the Q&A.